Grey
Brand Name(s):
Indication:refractory Focal Segmental Glomerulosclerosis in the native kidney in adults
Rationale:1
Considered:Aug-19
Review Date:Aug-24
Comments:
NHS England Policy Statement stating that no routine commissioning of this drug for this indication. This was due to a lack of clinical evidence available and availability of alternative therapies. (https://www.england.nhs.uk/wp-content/uploads/2019/07/1818-Policy-Statement)